A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5950 participants.

Also called NCT06627322

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 5,950 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06627322
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06627322. Randomized; no masking; primary purpose prevention. Start 2024-11-21 (actual); primary completion 2029-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)
Acronym
REMATCH
Intervention (Drug)
Dual-combination therapy
Intervention (Drug)
Triple-combination therapy
Intervention (Device)
Dexcom G7, Pasta
Lead sponsor
Kyu Chang Won (class: other)
Collaborator
Boryung Pharmaceutical Co., Ltd (class: industry)
Collaborator
Dong-A ST Co., Ltd. (class: industry)
Collaborator
HK inno.N Corporation (class: industry)
Collaborator
Daewoong Pharmaceutical Co. LTD. (class: industry)
Collaborator
Chong Kun Dang Pharmaceutical Corp. (class: industry)
Collaborator
Celltrion (class: industry)
Collaborator
Kakao Healthcare Corp. (class: not stated)
Collaborator
Handok Inc. (class: industry)

Record details

Record id
cardio:ct-nct06627322
Content hash
069df49621bc98cb09f138451cc0976e8f2c14ab07051af82682cdcf92a109ff